EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor–Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas

Rana R McKay iD, Renu Eapen, Elizabeth M Wulff-Burchfield, Michael S Hofman

American Society of Clinical Oncology Educational Book · 2025

DOI: 10.1200/edbk-25-473862 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2025. Verfasst von Rana R McKay und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Diego, La Jolla, CA. Hauptthemen laut MEDLINE: Immunoconjugates, Molecular Imaging, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel approaches in molecular imaging and targeted therapeutics are transforming the management of renal cell carcinoma (RCC) and urothelial carcinoma (UC). This review focuses on three key areas of innovation: molecular imaging, hypoxia-inducible factor-2α (HIF-2α) inhibition, and antibody-drug conjugates (ADCs). In molecular imaging, prostate-specific membrane antigen positron emission tomography/computed tomography has shown promise in RCC, while novel tracers targeting carbonic anhydrase IX and nectin-4 are emerging for RCC and UC, respectively. These approaches may enable better characterization of disease and treatment response monitoring. HIF-2α inhibition represents a breakthrough in targeting the fundamental pathobiology of clear cell RCC, with belzutifan demonstrating significant clinical benefit in both von Hippel-Lindau disease and sporadic RCC. Next-generation HIF-2α inhibitors, including casdatifan, show promising early clinical results with distinct pharmacologic properties. ADCs have become a cornerstone of UC treatment, with enfortumab vedotin plus pembrolizumab now approved as first-line therapy. Multiple human epidermal growth factor receptor 2 (HER2)-directed ADCs have shown efficacy in HER2-expressing UC, including trastuzumab deruxtecan, which recently received tumor-agnostic approval. While ADC development in RCC faces unique challenges, novel approaches including immunostimulatory payloads and bispecific antibodies are being explored. The integration of these advances in molecular imaging and therapeutics offers opportunities for more personalized treatment approaches in RCC and UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesMolecular ImagingCarcinoma, Renal CellKidney NeoplasmsUrogenital NeoplasmsBasic Helix-Loop-Helix ProteinsHumansMolecular Targeted TherapyEndothelial PAS Domain-Containing Protein 1

Substanzen

ImmunoconjugatesBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1

Autor:innen und Institutionen

  • University of California San Diego, La Jolla, CA.
  • Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • University of Melbourne, Melbourne, VIC, Australia.
  • University of Kansas Medical Center, Kansas City, KS.

ORCID-Profile: Rana R McKay

Zitieren

APA

McKay, R. R., Eapen, R., Wulff-Burchfield, E. M., & Hofman, M. S. (2025). Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor–Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk-25-473862

Vancouver

McKay RR, Eapen R, Wulff-Burchfield EM, Hofman MS. Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor–Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas. American Society of Clinical Oncology Educational Book. 2025. doi:10.1200/edbk-25-473862

BibTeX
@article{McKay2025,
  author = {McKay, Rana R and Eapen, Renu and Wulff-Burchfield, Elizabeth M and Hofman, Michael S},
  title = {Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor–Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2025},
  doi = {10.1200/edbk-25-473862}
}
Kostenlos starten →